Alto Neuroscience (ANRO) Change in Accured Expenses (2023 - 2026)

Alto Neuroscience has disclosed Change in Accured Expenses across 4 years of filings, most recently posting -$1.8 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$1.8 million, up 35.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $659000.0 (down 26.78% YoY), and the FY2025 annual result was -$289000.0, down 107.21% from the prior year.
• Change in Accured Expenses came in at -$1.8 million for Q1 2026 at Alto Neuroscience, down from $1.7 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.7 million in Q4 2025 to a low of -$2.7 million in Q1 2025.
• The 4-year median for Change in Accured Expenses is $406000.0 (2024), against an average of $123692.3.
• Peak annual rise in Change in Accured Expenses reached 323.6% in 2025, while the deepest fall reached 765.27% in 2025.
• Alto Neuroscience's Change in Accured Expenses stood at -$500000.0 in 2023, then surged by 182.2% to $411000.0 in 2024, then jumped by 323.6% to $1.7 million in 2025, then slumped by 200.69% to -$1.8 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.8 million (Q1 2026), $1.7 million (Q4 2025), and $208000.0 (Q3 2025), per Business Quant data.